Determine the necessary mass, volume, or concentration for preparing a solution.
This is a demo store. No orders will be fulfilled.
| SKU | Size | Availability |
Price | Qty |
|---|---|---|---|---|
|
K414099-2mg
|
2mg |
3
|
$56.90
|
|
|
K414099-5mg
|
5mg |
3
|
$117.90
|
|
|
K414099-10mg
|
10mg |
3
|
$177.90
|
|
|
K414099-25mg
|
25mg |
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
|
$400.90
|
|
|
K414099-50mg
|
50mg |
2
|
$622.90
|
|
IRE1 Inhibitors
| Synonyms | EN300-195606 | 1589527-65-0 | AC-36160 | SCHEMBL16964584 | Z2689324163 | s8658 | CCG-269842 | KIRA 6 | NOHQEAFAESMMDX-UHFFFAOYSA-N | EX-A2581 | AB90807 | Urea, N-[4-[8-amino-3-(1,1-dimethylethyl)imidazo[1,5-a]pyrazin-1-yl]-1-naphthalenyl]-N'-[3-(trifluoro |
|---|---|
| Specifications & Purity | ≥98% |
| Biochemical and Physiological Mechanisms | kira6 is a potent type II IRE1α kinase inhibitor with an IC50 of 0.6 μM. It dose-dependently inhibits IRE1α(WT) kinase activity, XBP1 RNA cleavage, Ins2 RNA cleavage and oligomerization. |
| Storage Temp | Store at -20°C |
| Shipped In |
Ice chest + Ice pads This product requires cold chain shipping. Ground and other economy services are not available. |
| Product Description |
Information kira6 kira6 is a potent type II IRE1α kinase inhibitor with an IC50 of 0.6 μM. It dose-dependently inhibits IRE1α(WT) kinase activity, XBP1 RNA cleavage, Ins2 RNA cleavage and oligomerization. Targets IRE1α (Cell-free) 0.6 μM In vitro In INS-1 cells, KIRA6 inhibits IRE1α auto-phosphorylation by Tg and XBP1 mRNA splicing by Tm in a dose-dependent manner. In vivo Intravitreally, KIRA6 preserves photoreceptor functional viability in rat models of ER stress-induced retinal degeneration. Systemically, KIRA6 preserves pancreatic β-cells, increases insulin, and reduces hyperglycemia in Akita diabetic mice. KIRA6 inhibits IRE1α in vivo to preserve cell viability and function in diverse cells and rodent tissues experiencing ER stress. The pharmacokinetic profile of KIRA6 in BALB/c mice intraperitoneally (i.p.) dosed at 10 mg/kg shows good drug plasma AUC levels (AUC 0-24h = 14.3 μM*h) with moderate clearance (22.4 mL/min/kg). Drug half-life is 3.90 hours, Cmax is 3.3 μM, and plasma levels at 4 and 8hr are 1.2 μM and 0.33 μM, respectively. |
Taxonomy Tree
| Kingdom | Organic compounds |
|---|---|
| Superclass | Benzenoids |
| Class | Naphthalenes |
| Subclass | Not available |
| Intermediate Tree Nodes | Not available |
| Direct Parent | Naphthalenes |
| Alternative Parents | Trifluoromethylbenzenes N-phenylureas Imidazo[1,5-a]pyrazines Aminopyrazines N-substituted imidazoles Imidolactams Heteroaromatic compounds Ureas Azacyclic compounds Primary amines Organofluorides Organic oxides Hydrocarbon derivatives Carbonyl compounds Alkyl fluorides |
| Molecular Framework | Aromatic heteropolycyclic compounds |
| Substituents | Trifluoromethylbenzene - N-phenylurea - Naphthalene - Imidazo[1,5-a]pyrazine - Aminopyrazine - Monocyclic benzene moiety - Imidolactam - Pyrazine - N-substituted imidazole - Azole - Imidazole - Heteroaromatic compound - Urea - Azacycle - Organoheterocyclic compound - Alkyl fluoride - Organofluoride - Organohalogen compound - Organonitrogen compound - Organooxygen compound - Primary amine - Hydrocarbon derivative - Carbonyl group - Organic oxide - Organic oxygen compound - Organic nitrogen compound - Amine - Alkyl halide - Aromatic heteropolycyclic compound |
| Description | This compound belongs to the class of organic compounds known as naphthalenes. These are compounds containing a naphthalene moiety, which consists of two fused benzene rings. |
| External Descriptors | Not available |
|
|
|
| ALogP | 5.531 |
|---|---|
| hba_count | 3 |
| HBD Count | 3 |
| Rotatable Bond | 5 |
| Pubchem Sid | 504772329 |
|---|---|
| Pubchem Sid Url | https://pubchem.ncbi.nlm.nih.gov/substance/504772329 |
| IUPAC Name | 1-[4-(8-amino-3-tert-butylimidazo[1,5-a]pyrazin-1-yl)naphthalen-1-yl]-3-[3-(trifluoromethyl)phenyl]urea |
| INCHI | InChI=1S/C28H25F3N6O/c1-27(2,3)25-36-22(23-24(32)33-13-14-37(23)25)20-11-12-21(19-10-5-4-9-18(19)20)35-26(38)34-17-8-6-7-16(15-17)28(29,30)31/h4-15H,1-3H3,(H2,32,33)(H2,34,35,38) |
| InChIKey | NOHQEAFAESMMDX-UHFFFAOYSA-N |
| Smiles | CC(C)(C)C1=NC(=C2N1C=CN=C2N)C3=CC=C(C4=CC=CC=C43)NC(=O)NC5=CC=CC(=C5)C(F)(F)F |
| Isomeric SMILES | CC(C)(C)C1=NC(=C2N1C=CN=C2N)C3=CC=C(C4=CC=CC=C43)NC(=O)NC5=CC=CC(=C5)C(F)(F)F |
| Molecular Weight | 518.53 |
| Reaxy-Rn | 29115164 |
| Reaxys-RN_link_address | https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN=29115164&ln= |
Find and download the COA for your product by matching the lot number on the packaging.
| Lot Number | Certificate Type | Date | Item |
|---|---|---|---|
| Certificate of Analysis | Jun 10, 2025 | K414099 | |
| Certificate of Analysis | Jun 10, 2025 | K414099 | |
| Certificate of Analysis | Jun 10, 2025 | K414099 | |
| Certificate of Analysis | Jul 05, 2022 | K414099 |
| Solubility | Solubility (25°C) In vitro DMSO: 60 mg/mL (115.71 mM); Ethanol: 60 mg/mL (115.71 mM); Water: Insoluble; |
|---|---|
| DMSO(mg / mL) Max Solubility | 60 |
| DMSO(mM) Max Solubility | 115.7117235 |
| Water(mg / mL) Max Solubility | <1 |
| Molecular Weight | 518.500 g/mol |
| XLogP3 | 6.500 |
| Hydrogen Bond Donor Count | 3 |
| Hydrogen Bond Acceptor Count | 7 |
| Rotatable Bond Count | 4 |
| Exact Mass | 518.204 Da |
| Monoisotopic Mass | 518.204 Da |
| Topological Polar Surface Area | 97.300 Ų |
| Heavy Atom Count | 38 |
| Formal Charge | 0 |
| Complexity | 834.000 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| The total count of all stereochemical bonds | 0 |
| Covalently-Bonded Unit Count | 1 |